Cromolyn sodium
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Cromolyn sodium
- Molecular weight
- 512.33
- Structure (SMILES)
- O=C([O-])c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)[O-])cc(=O)c34)cccc2o1.[Na+].[Na+]
- aerocrom
- Aerocrom
- allercrom
- Allercrom
- aspire
- Aspire
- brol eze
- Brol-eze
- catacrom
- Catacrom
- clariteyes
- Clariteyes
- crolom
- Crolom
- cromogen
- Cromogen
- cromogen e breathe
- Cromogen e-breathe
- cromolux
- Cromolux
- cromolyn sodium
- Cromolyn sodium
- cromoptic
- Cromoptic
- cromosol
And 53 more, listed on the interactive page.
- 4h 1 benzopyran 2 carboxylic acid 5 5 2 hydroxy 1 3 propanediyl bis oxy bis 4 oxo disodium salt
- 4H-1-BENZOPYRAN-2-CARBOXYLIC ACID, 5,5'-((2-HYDROXY-1,3-PROPANEDIYL)BIS(OXY))BIS(4-OXO-, DISODIUM SALT)
- astilyn
- Astilyn
- cromoglicate sodium
- Cromoglicate sodium
- Cromoglicate sodium [WHO-DD]
- cromoglicate sodium who dd
- cromoglycic acid
- Cromoglycic acid
- cromolyn disodium salt
- Cromolyn disodium salt
- CROMOLYN DISODIUM SALT [MI]
- cromolyn disodium salt mi
- cromolyn sodium
- Cromolyn sodium
- CROMOLYN SODIUM [ORANGE BOOK]
- CROMOLYN SODIUM [USAN]
- CROMOLYN SODIUM [USP MONOGRAPH]
- CROMOLYN SODIUM [USP-RS]
- CROMOLYN SODIUM [VANDF]
- cromolyn sodium orange book
- cromolyn sodium usan
- cromolyn sodium usp monograph
- cromolyn sodium usp rs
And 30 more, listed on the interactive page.
- CAS registry numbers
- 15826-37-6
- ChEMBL ID
- CHEMBL74
- InChIKey
- VLARUOGDXDTHEH-UHFFFAOYSA-L
- RxNorm IDs (RxCUI)
- 3538
- FDA ingredient codes (UNII)
- Q2WXR1I0PK
- 27503
- 59057527
- Applicant
- VIATRIS SPECIALTY
- Approval date
- 29 Feb 1996
- Application number
- NDA020479
- Patents
- 0
- Designations
- 5
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Pharmacology name
- cromoglicic acid
- Type
- Synthetic organic
Administration routes
- Oral
- topical
- Action type
- Agonist
- Target
- <i>TAS2R20</i>
- Gene symbol
- <i>TAS2R20</i>
- Action type
- Agonist
- Target
- <i>TAS2R7</i>
- Gene symbol
- <i>TAS2R7</i>
- Condition
- Prostatitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003830
- Subject identifier
- D011472
- Condition
- Urticaria
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005531
- Subject identifier
- D014581
- Condition
- Triple Negative Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005537
- Subject identifier
- D064726
- Condition
- Conjunctivitis, Allergic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007141
- Subject identifier
- D003233
- Condition
- Mastocytosis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0009001
- Subject identifier
- D008415
- Condition
- Rosacea
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000760
- Subject identifier
- D012393
- Condition
- Vomiting
- Highest recorded phase
- 4
- Condition identifier
- HP:0002013
- Subject identifier
- D014839
- Condition
- Abdominal Pain
- Highest recorded phase
- 4
- Condition identifier
- HP:0002027
- Subject identifier
- D015746
- Condition
- Headache
- Highest recorded phase
- 4
- Condition identifier
- HP:0002315
- Subject identifier
- D006261
- Condition
- Asthma
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003830
- Condition identifier
- EFO_0005531
- Condition identifier
- EFO_0007141
- Condition identifier
- EFO_0009001
- Condition identifier
- HP_0002013
- Condition identifier
- HP_0002013
- Highest recorded phase
- 4
- Condition identifier
- HP_0002027
- Condition identifier
- HP_0002027
- Highest recorded phase
- 4
- Condition identifier
- HP_0002315
- Condition identifier
- HP_0002315
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004979
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005275
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005492
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005642
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006604
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007950
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0019023
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019091
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0022103
- Highest recorded phase
- 1
- Event
- anaphylactic reaction
- Reports
- 9
- Reporting signal score
- 8.52831
- Event
- behaviour disorder
- Reports
- 5
- Reporting signal score
- 16.1192
- Event
- blood glucose increased
- Reports
- 9
- Reporting signal score
- 8.3101
- Event
- blood pressure increased
- Reports
- 11
- Reporting signal score
- 8.94438
- Event
- bone pain
- Reports
- 9
- Reporting signal score
- 11.1966
- Event
- conjunctivitis allergic
- Reports
- 2
- Reporting signal score
- 6.57489
- Event
- diffuse cutaneous mastocytosis
- Reports
- 1
- Reporting signal score
- 6.32435
- Event
- drug hypersensitivity
- Reports
- 17
- Reporting signal score
- 7.68604
- Event
- eye irritation
- Reports
- 5
- Reporting signal score
- 7.09105
- Event
- flushing
- Reports
- 9
- Reporting signal score
- 8.14159
- Event
- gastric cancer stage 0
- Reports
- 2
- Reporting signal score
- 14.7505
- Event
- headache
- Reports
- 1
- Reporting signal score
- 7.1035
- Event
- hypersensitivity
- Reports
- 21
- Reporting signal score
- 21.9017
- Event
- injection site pruritus
- Reports
- 9
- Reporting signal score
- 8.96297
- Event
- leukocytoclastic vasculitis
- Reports
- 6
- Reporting signal score
- 20.6659
- Event
- mast cell activation syndrome
- Reports
- 6
- Reporting signal score
- 31.8922
- Event
- mastocytosis
- Reports
- 9
- Reporting signal score
- 54.9809
- Event
- nausea
- Reports
- 2
- Reporting signal score
- 8.54434
- Event
- osteoporosis
- Reports
- 9
- Reporting signal score
- 17.7215
- Event
- perfume sensitivity
- Reports
- 11
- Reporting signal score
- 68.5059
- Event
- scratch
- Reports
- 9
- Reporting signal score
- 30.7259
- Event
- skin reaction
- Reports
- 9
- Reporting signal score
- 22.2989
- Event
- systemic mastocytosis
- Reports
- 3
- Reporting signal score
- 15.1443
- Event
- treatment failure
- Reports
- 204
- Reporting signal score
- 851.817
- Event
- tubulointerstitial nephritis
- Reports
- 7
- Reporting signal score
- 12.7071
And 3 more, listed on the interactive page.
- NCT00777348
- NCT01933464
- NCT03167216
- NCT05076682
- Dose
- 1 or 2 drops
- Route
- Ocular
- How often
- 4 to 6 times a day
Conditions of use
- Use at regular intervals
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 3
- Polar surface area
- 173.71
- Calculated partition coefficient (ALogP)
- 2.11
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 36
- Molecular formula
- C23H14Na2O11
- Monoisotopic mass
- 512.03314982
- Natural product
- Yes
- 0037-0678
- 0172-6406
- 16571-600
- 42571-132
- 61314-237
- 71205-230
- 81665-104
- 50090-1202
- 68788-8490
- Recorded assays
- 1,354
- Active assays
- 21
Active assay types
- Confirmatory
- Mast Cell Stabilizers
- Anti-Asthmatic Agents
Related records
Trials (27)
- A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux® (Cetuximab) in Healthy Adult Male Chinese Subjects
- A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
- A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
- An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
- Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis
- Cromoglicate in Mastocytosis
- Cromoglicate in Psoriasis
- Cromolyn Detection of Silent Aspiration
- Cromolyn Sodium for Treatment of COVID-19 Pneumonia
- Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)
- Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus
- Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial
- Influence of Cromones on Eucapnic Hyperventilation (EVH)-Test in Young (Elite) Athletes Who Tested Positive for EIB.
- Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
- Mast Cell Treatment in Post-tick Bite Illness (PTBI)
- Mast Cells in Acid-induced Intestinal Permeability
- Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction
- Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
- Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis
- Orphan Indications for CD19 Redirected Autologous T Cells
Approved for (4)
- Asthma
- Atopic conjunctivitis
- Mastocytosis
- Urticaria
In development for (3)
- Prostatitis Early phase 1
- Rosacea Phase 1
- Triple-negative breast carcinoma Phase 2